stoxline Quote Chart Rank Option Currency Glossary
  
(RVMD)
  0 (0%)    03-28 20:26
Open:
High:
Volume: 0
  
Pre. Close:
Low:
Market Cap: 0(M)
Technical analysis
2024-03-28 4:54:03 PM
Short term     
Mid term     
Targets 6-month :  40.4 1-year :  47.18
Resists First :  34.59 Second :  40.4
Pivot price 31.75
Supports First :  31.1 Second :  28.95
MAs MA(5) :  31.03 MA(20) :  31.39
MA(100) :  27.34 MA(250) :  26.93
MACD MACD :  0.3 Signal :  0.4
%K %D K(14,3) :  32 D(3) :  24.9
RSI RSI(14): 57.4
52-week High :  35.59 Low :  15.43
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ RVMD ] has closed below upper band by 38.2%. Bollinger Bands are 10.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 32.54 - 32.69 32.69 - 32.83
Low: 31.04 - 31.22 31.22 - 31.38
Close: 31.93 - 32.23 32.23 - 32.5
Company Description

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Headline News

Thu, 28 Mar 2024
Revolution Medicines, Inc. (NASDAQ:RVMD) General Counsel Jeff Cislini Sells 1,500 Shares - MarketBeat

Wed, 27 Mar 2024
How Will the Market React to Revolution Medicines Inc (RVMD) Stock Getting a Bearish Rating - InvestorsObserver

Mon, 25 Mar 2024
(RVMD) On The My Stocks Page - Stock Traders Daily

Mon, 25 Mar 2024
Where Does Revolution Medicines Inc (RVMD) Stock Fall in the Biotechnology Field After It Has Fallen -0.97% This Week? - InvestorsObserver

Mon, 25 Mar 2024
Comparing Revolution Medicines (NASDAQ:RVMD) & Semper Paratus Acquisition (NASDAQ:LGST) - Defense World

Wed, 28 Feb 2024
Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 165 (M)
Held by Insiders 1.6083e+008 (%)
Held by Institutions 2.4 (%)
Shares Short 16,950 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -4.5668e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -20 %
Return on Assets (ttm) 819.8 %
Return on Equity (ttm) -20.1 %
Qtrly Rev. Growth 1.158e+007 %
Gross Profit (p.s.) -62.23
Sales Per Share -22.72
EBITDA (p.s.) 0
Qtrly Earnings Growth -3.9 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -351 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -1.42
Price to Cash Flow 4.44
Stock Dividends
Dividend 0
Forward Dividend 1.715e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android